Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03025477 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer

Study acronym: CHIMOVIP
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 11, 2021 (before its estimated October 2021 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Oct 2019 to Oct 2021
    • Study completion date: Oct 2030 to Oct 2032
    v4
  2. Primary completion date: Oct 2018 to Oct 2019
    • Study completion date: Oct 2029 to Oct 2030
    • Site contacts updated at 2 of 7 sites
    v3
  3. Start date: May 2016 to Oct 2016
    • Primary completion date: May 2018 to Oct 2018
    • Study completion date: May 2029 to Oct 2029
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
CHIMOVIP is a study to determine the best therapeutic strategy in patient with ovarian advanced cancer.
Trial Details
NCT Number NCT03025477
Lead Sponsor Groupe Hospitalier Diaconesses Croix Saint-Simon
Collaborators: GERCOR - Multidisciplinary Oncology Cooperative Group
Conditions
(from sponsor)		 Ovarian Cancer, Epithelial
Related terms Carcinoma, Ovarian Epithelial
Enrollment 84 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov